GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (CHIX:SANNz) » Definitions » Altman Z-Score

Santhera Pharmaceuticals Holding AG (CHIX:SANNZ) Altman Z-Score : -2.78 (As of Dec. 13, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Santhera Pharmaceuticals Holding AG Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of -3.01 is in distress zone. This implies bankruptcy possibility in the next two years.

Santhera Pharmaceuticals Holding AG has a Altman Z-Score of -2.78, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Santhera Pharmaceuticals Holding AG's Altman Z-Score or its related term are showing as below:

CHIX:SANNz' s Altman Z-Score Range Over the Past 10 Years
Min: -16.64   Med: -3.63   Max: 28.51
Current: -3.01

During the past 13 years, Santhera Pharmaceuticals Holding AG's highest Altman Z-Score was 28.51. The lowest was -16.64. And the median was -3.63.


Santhera Pharmaceuticals Holding AG Altman Z-Score Historical Data

The historical data trend for Santhera Pharmaceuticals Holding AG's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santhera Pharmaceuticals Holding AG Altman Z-Score Chart

Santhera Pharmaceuticals Holding AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.90 -9.82 -9.62 -16.64 -2.84

Santhera Pharmaceuticals Holding AG Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -16.64 - -2.84 -

Competitive Comparison of Santhera Pharmaceuticals Holding AG's Altman Z-Score

For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santhera Pharmaceuticals Holding AG's Altman Z-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Santhera Pharmaceuticals Holding AG's Altman Z-Score falls into.



Santhera Pharmaceuticals Holding AG Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Santhera Pharmaceuticals Holding AG's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*-0.0881+1.4*-5.2242+3.3*0.6945+0.6*2.3342+1.0*0.9433
=-2.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was CHF109.6 Mil.
Total Current Assets was CHF34.7 Mil.
Total Current Liabilities was CHF44.3 Mil.
Retained Earnings was CHF-572.7 Mil.
Pre-Tax Income was CHF54.8 Mil.
Interest Expense was CHF-21.3 Mil.
Revenue was CHF103.4 Mil.
Market Cap (Today) was CHF116.0 Mil.
Total Liabilities was CHF49.7 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(34.657 - 44.315)/109.629
=-0.0881

X2=Retained Earnings/Total Assets
=-572.719/109.629
=-5.2242

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(54.82 - -21.314)/109.629
=0.6945

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=115.976/49.686
=2.3342

X5=Revenue/Total Assets
=103.414/109.629
=0.9433

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Santhera Pharmaceuticals Holding AG has a Altman Z-Score of -2.78 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Santhera Pharmaceuticals Holding AG  (CHIX:SANNz) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Santhera Pharmaceuticals Holding AG Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Santhera Pharmaceuticals Holding AG's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Santhera Pharmaceuticals Holding AG Business Description

Traded in Other Exchanges
Address
Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives the majority of its revenue from the European Union.

Santhera Pharmaceuticals Holding AG Headlines

No Headlines